Cansino Biologics Inc. (688185.SH) stated on the investor interactive platform on June 19 that the expanded clinical study of the company's four-valent meningo combination vaccine for the 4-6 year old age group has completed enrollment and is currently undergoing follow-up visits and sample collection according to plan.
康希诺(688185.SH)：四价流脑结合疫苗扩龄临床已完成入组
Cansino Biologics Inc. (688185.SH): Clinical trials for quadrivalent meningococcal combination vaccine expansion have completed enrollment.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.